UTI Small Cap Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of small cap companies.
Growthvine rating: 2/5 — ranked #22 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹26.37 (as of 2026-10-01) |
|---|
| AUM | ₹5,448 Cr |
|---|
| Expense ratio | 1.59% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nitin Jain |
|---|
| Exit load | 1% for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 12.85% |
|---|
| Sharpe ratio | 0.47 |
|---|
| Standard deviation | 19.59% |
|---|
| Max drawdown | −22.54% |
|---|
| Alpha | 0.26 |
|---|
| Beta | 0.88 |
|---|
Over 5 years, captured 81.2% of NIFTY Smallcap 250's upside and 76.8% of its downside.
Market cap allocation
| Large cap | 0.0% |
|---|
| Mid cap | 18.3% |
|---|
| Small cap | 81.7% |
|---|
Concentration
| Top 5 holdings | 11.4% |
|---|
| Top 10 holdings | 20.1% |
|---|
| Total holdings | 108 |
|---|
| Index overlap | 23.2% |
|---|
| Active share | 76.8% |
|---|
Top holdings
- NET CURRENT ASSETS — 4.0%
- Navin Fluorine International Limited — 2.5%
- Karur Vysya Bank Ltd. — 2.5%
- ACUTAAS CHEMICALS LIMITED — 2.3%
- Ujjivan Small Finance Bank Limited — 2.2%
- TD Power Systems Limited — 1.9%
- City Union Bank Ltd — 1.8%
- Aster DM Healthcare Limited — 1.8%
- Marksans Pharma Ltd. — 1.8%
- AFFLE 3I LIMITED — 1.7%
Top sectors
- Banking & Financial — 12.3%
- Pharma & Biotech — 10.8%
- Industrial Products — 9.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.1% | Q4 (Bottom) | #31 of 34 |
| 2025 | −5.3% | Q3 | #21 of 30 |
| 2024 | 26.8% | Q2 | #10 of 28 |
| 2023 | 35.3% | Q3 | #18 of 24 |
| 2022 | −0.6% | Q3 | #12 of 22 |